BLU News and Press, BELLUS Health Inc. From 05/25/21

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...

In alphabetical order, what do Alcanna (TSX: CLIQ) , BELLUS Health (TSX:BLU) (NASDAQ:BLU) , Cineplex (TSX:CGX) , and Diversified Royalty (TSX:DIV) have in common? Well, these four stocks are the top buys on the TSX in May 2021. If you have $2,000 ...

Bellus Health (TSX:BLU) (NASDAQ:BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hyper-sensitization disorders. The company is developing BLU-5937 for the treatment of chronic cough. Hyper-sensi...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today a...

BELLUS Health (BLU): Q1 GAAP EPS of -$0.20 misses by $0.06.Revenue of $4K (flat Y/Y).Press Release For further details see: BELLUS Health EPS misses by $0.06

- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until en...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appoin...

NEW YORK, March 19, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against BELLUS Health Inc. (“BELLUS”) (NASDAQ: BLU) in the United States District Court for the Southern District of New York on behalf of those who ...